Outcomes of vedolizumab therapy in patients with immune checkpoint inhibitor–induced colitis: a multi-center study

Table 3 Treatment for colitis and outcomes (n = 28)

Characteristic	No. of patients (%)
Treatment
Mean overall duration of steroid therapy, days (SD)	96 (74)
Diarrhea refractory to steroids	28 (100)
Infliximab therapy	9 (32)
Median no. of infliximab doses (IQR)	2 (1–3)
Recurrent symptoms while receiving infliximab	9 (100)
Median no. of vedolizumab doses (IQR)	3 (1–4)
Outcomes
Median duration from 1st vedolizumab to improvement, days (IQR)	5 (1–30)
Mean duration of endoscopic follow-up, months (SD)	6 (4)
Clinical remission at last follow-up	24 (86)
Endoscopic remission at last follow-up^a	7 (54)
Histologic remission at last follow-up^a	5 (29)

Abbreviations: SD, standard deviation; IQR, interquartile range.
^aRepeat endoscopic and histologic evaluations were performed in 17 patients. However, endoscopic remission was counted for only 13 patients who had abnormal endoscopic findings initially and had repeat evaluation